BridGene Biosciences Appoints David Sperandio, Ph.D., as Head of Chemistry

SAN JOSE, CA., August 1, 2022 /PRNewswire/ — BridGene Biosciences, Inc., a biotechnology company using proprietary chemoproteomics technology to discover and develop small molecules for high-value, traditionally non-drug targets, today announced that David SperandioPh.D., a medicinal chemist with over 20 years of experience, joined the company as head of chemistry.

Dr. Sperandio, inventor of 23 patents and author of 25 peer-reviewed publications, has extensive experience leading cross-functional teams from molecule discovery to IND filing. Dr. Sperandio will lead BridGene’s chemistry team and oversee research on covalent chemistry, chemical proteomics and quantitative mass spectrometry as methods for identifying non-drug targets. Additionally, Dr. Sperandio will be responsible for advancing BridGene’s internal pipeline of first-in-class drugs for hard-to-treat targets in oncology.

Co-founder and CEO of BridGene Ping CaoPh.D., commented, “David’s addition to our leadership team and recent Series B funding strengthens BridGene’s capabilities to use IMTAC™ to discover new drugs for novel and traditionally unsuitable targets. David’s leadership and experience will help expand BridGene’s library of molecules to identify potential drug candidates as we aim to advance a first-in-class drug pipeline for these new targets. »

Dr. Sperandio most recently served as Executive Director at Biomea Fusion, where he led the team that identified BMF-500, a potential best-in-class targeted covalent FLT-3 inhibitor for the treatment of acute myeloid leukemia. Prior to joining Biomea Fusion, Sperandio led a collaboration between R2M Pharma Inc. and Tenaya Therapeutics Inc., which discovered novel HDAC6 inhibitors for cardiovascular disease and played a key role in the clinical development of TN-301, a treatment experimental heart failure. Dr. Sperandio began his career at Celera Corp. and focused on the structure-guided discovery of covalent reversible serine protease inhibitors. He then joined Gilead Sciences Inc., where he led the chemistry team that discovered Alobresib (GS-5829), a novel BRD4 inhibitor for prostate cancer, and Presatorvir (GS-5806) , the first small molecule RSV fusion inhibitor that has reached the clinic and has shown proof of concept in humans.

Dr. Sperandio commented, “I am delighted to join BridGene at such a dynamic time for the company. 2022 has been a remarkable year so far, and I look forward to working closely with the leadership team to continue to drive the success of IMTAC™.”

Dr. Sperandio received his doctorate in organic chemistry from the University of Zürich and completed his postdoctoral research at Stanford University.

About BridGene Biosciences
BridGene is a biotechnology company focused on the discovery and development of innovative small molecules that address traditionally unusable targets, providing new avenues to treat disease. Using its proprietary chemoproteomics platform, IMTAC™, BridGene can screen small molecules against proteins in living cells to discover drug candidates for high-value, traditionally tamper-proof targets. To this end, BridGene leverages its proprietary and diverse library of drug-like tagged small molecules. The ultimate goal is to enable breakthrough small molecule drug discovery with expanded mechanisms to treat diseases with targets previously inaccessible to small molecules. BridGene’s unique technology allows it to perform IMTAC™ screening for covalent and non-covalent molecules, target different amino acids and discover new targets for disease treatment by deconvoluting phenotypic screening results. The company is advancing a diverse pipeline of first-in-class drugs for targets in multiple disease areas. For more information, visit


Tiberend Strategic Advisors, Inc.


Jonathan Nugent
[email protected]


Bill Borden
[email protected]

Dave Schemelia
[email protected]

Quote See original content to download multimedia:

SOURCE BridGene Biosciences